why choose us

First received: July 11, 2025

Clinical Trial: A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Autoimmune Hemolytic Anemia

Study Type: INTERVENTIONAL


Official Title: The Safety and Efficacy of YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy

Brief Summary: This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 STAR-T cell therapy in patients with autoimmune hemolytic anemia who have failed ?3 lines of therapy.The objective is to evaluate the safety, preliminary efficacy, pharmacokinetics/pharmacodynamics (PK/PD), and immune cell reconstitution characteristics of YTS109 cell therapy in Multi-rAIHA subjects…

Read more